Related references
Note: Only part of the references are listed.Back on target
Sarah Webb
NATURE BIOTECHNOLOGY (2013)
Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature
Martina Steiner et al.
CHEMICAL SCIENCE (2013)
Synthetically defined glycoprotein vaccines: current status and future directions
Roberto Adamo et al.
CHEMICAL SCIENCE (2013)
A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy
Goncalo J. L. Bernardes et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format
Kathrin Zuberbuehler et al.
CHEMICAL COMMUNICATIONS (2012)
Antibody-drug conjugates: Basic concepts, examples and future perspectives
Giulio Casi et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Site-Specific Traceless Coupling of Potent Cytotoxic Drugs to Recombinant Antibodies for Pharmacodelivery
Giulio Casi et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Peter D. Senter et al.
NATURE BIOTECHNOLOGY (2012)
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Ben-Quan Shen et al.
NATURE BIOTECHNOLOGY (2012)
Site-specific chemical protein conjugation using genetically encoded aldehyde tags
David Rabuka et al.
NATURE PROTOCOLS (2012)
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Jun Y. Axup et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A Tag-and-Modify Approach to Site-Selective Protein Modification
Justin M. Chalker et al.
ACCOUNTS OF CHEMICAL RESEARCH (2011)
Design of Antibody-Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism
Xiuxia Sun et al.
BIOCONJUGATE CHEMISTRY (2011)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models
Robert M. Sharkey et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Pharma interest surges in antibody drug conjugates
Sarah Webb
NATURE BIOTECHNOLOGY (2011)
Choosing an effective protein bioconjugation strategy
Nicholas Stephanopoulos et al.
NATURE CHEMICAL BIOLOGY (2011)
Design and Application of Antibody Cysteine Variants
Vladimir Voynov et al.
BIOCONJUGATE CHEMISTRY (2010)
What's fueling the biotech engine-2009-2010
Saurabh Aggarwal
NATURE BIOTECHNOLOGY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
Ellen M. Sletten et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2009)
Potent antibody drug conjugates for cancer therapy
Peter D. Senter
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Antibody drug-conjugates targeting the tumor vasculature Current and future developments
Hans-Peter Gerber et al.
MABS (2009)
Targeted cancer therapy: Conferring specificity to cytotoxic drugs
Ravi V. J. Chari
ACCOUNTS OF CHEMICAL RESEARCH (2008)
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo
Alessandra Villa et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Anti-CD30 diabody-drug conjugates with potent antitumor activity
Kristine M. Kim et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
The extra-domain a of fibronectin is a vascular marker of solid tumors and Metastases
Jascha-N. Rybak et al.
CANCER RESEARCH (2007)
Introducing genetically encoded aldehydes into proteins
Isaac S. Carrico et al.
NATURE CHEMICAL BIOLOGY (2007)
Structural characterization of the maytansinoid -: monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry
LT Wang et al.
PROTEIN SCIENCE (2005)
Engineered antibody fragments and the rise of single domains
P Holliger et al.
NATURE BIOTECHNOLOGY (2005)
Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin
L Borsi et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Share Paper
